Provided by Tiger Trade Technology Pte. Ltd.

Incyte

113.13
-0.3100-0.27%
Volume:960.06K
Turnover:107.17M
Market Cap:22.93B
PE:14.41
High:113.69
Open:112.89
Low:110.08
Close:113.44
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.66
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.61
PE(LYR):17.65

Loading ...

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Benzinga Earnings
·
Jul 29

Incyte Says Opzelura Cream Approved in EU to Treat Moderate Atopic Dermatitis

MT Newswires Live
·
Jul 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)

TIPRANKS
·
Jul 29

Incyte is Maintained at Overweight by Barclays

Dow Jones
·
Jul 29

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte : Morgan Stanley Raises Target Price to $119 from $104

THOMSON REUTERS
·
Jul 29

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte price target raised to $119 from $104 at Morgan Stanley

TIPRANKS
·
Jul 29

Incyte says EC approves Opzelura cream for treatment of AD

TIPRANKS
·
Jul 29

Incyte price target raised to $140 from $136 at BofA

TIPRANKS
·
Jul 29

Incyte : H.c. Wainwright Raises Target Price to $150 from $140

THOMSON REUTERS
·
Jul 29

Opzelura® (Ruxolitinib) Cream Becomes First Steroid-Free Topical Jak Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

THOMSON REUTERS
·
Jul 29

Incyte Corporation : Barclays Raises Target Price to $139 from $134

THOMSON REUTERS
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), Centene (CNC) and Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte : Guggenheim Raises Target Price to $150 from $136

THOMSON REUTERS
·
Jul 29

Incyte Corp. Stock Advances 9.3%, Outperforms Peers

Dow Jones
·
Jul 29

Incyte up over 10%, on Track for Highest Close Since September 2017

Dow Jones
·
Jul 29

Incyte Reports Strong Commercial Growth with 38% Revenue Surge and Upgraded Full-Year Forecast

Deep News
·
Jul 29

Incyte Says It's No Longer A One-Drug Story

Benzinga Earnings
·
Jul 29

Top Midday Gainers

MT Newswires Live
·
Jul 29